TYK-00540 clinical trials
Also written TYK-00540.
How each study uses TYK-00540 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the TYK-00540 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- TYK-00540
- 3
Studies by the year they started
3 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2024 | 2 |
| 2025 | 1 |
Who runs them
Industry 3 · Other 0
TYK Medicines, Inc (3)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test TYK-00540.
- Nov 2026Study of TYK-00540 Combined With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer(mCRPC)Phase 1/2 · TYK Medicines, Inc
- Dec 2026A Study of TYK-00540 in Adult Patients With Solid TumorsPhase 1 · TYK Medicines, Inc
Studies
Open first, then newest update. How each study uses TYK-00540 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Study of TYK-00540 Combined With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer(mCRPC)Not yet recruitingPhase 1/2TYK Medicines, IncNCT07104643Written as TYK-00540
- Study of TYK-00540 Tablets in Patients With Advanced Solid TumorsRecruitingPhase 1/2TYK Medicines, IncNCT06950086Written as TYK-00540
- A Study of TYK-00540 in Adult Patients With Solid TumorsRecruitingPhase 1TYK Medicines, IncNCT06246071Written as TYK-00540